Antioxidative Self-Assembling Nanoparticles Attenuate the Development of Steatohepatitis and Inhibit Hepatocarcinogenesis in Mice

• Main Authors: Takahisa Watahiki (Author), Kosuke Okada (Author), Ikuru Miura (Author), Keii To (Author), Seiya Tanaka (Author), Eiji Warabi (Author), Naomi Kanno (Author), Kenji Yamagata (Author), Naohiro Gotoh (Author), Hideo Suzuki (Author), Shunichi Ariizumi (Author), Kiichiro Tsuchiya (Author), Yukio Nagasaki (Author), Junichi Shoda (Author)
• Format: Book
• Published: MDPI AG, 2022-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Oxidative stress (OS) contributes to nonalcoholic steatohepatitis (NASH) and hepatocarcinogenesis. We investigated whether antioxidative self-assembling nanoparticles (SMAPo^TN) could reduce the development of NASH and hepatocellular carcinoma (HCC) in <i>p62/Sqstm1</i> and <i>Nrf2</i> double knockout (DKO) mice and studied protective mechanisms. We measured disease development in male DKO mice fed a normal chow (NASH model) or a 60% high-fat diet (HFD; HCC model) with or without SMAPo^TN administration for 26 weeks. SMAPo^TN inhibited liver fibrosis in both groups and prevented HCC development (0% vs. 33%, <i>p</i> < 0.05) in the HFD group. SMAPo^TN reduced OS, inflammatory cytokine signaling, and liver fibrosis. RNA-sequencing revealed that SMAPo^TN decreased endoplasmic reticulum stress signaling genes in both groups, HCC driver genes, and cancer pathway genes, especially PI3K-AKT in the HFD groups. In the SMAPo^TN treatment HFD group, serum lipopolysaccharide levels and liver lipopolysaccharide-binding protein expression were significantly lower compared with those in the nontreatment group. SMAPo^TN improved the α-diversity of gut microbiota, and changed the microbiota composition. Oral SMAPo^TN administration attenuated NASH development and suppressed hepatocarcinogenesis in DKO mice by improving endoplasmic reticulum stress in the liver and intestinal microbiota. SMAPo^TN may be a new therapeutic option for NASH subjects and those with a high HCC risk.

Item Description

10.3390/antiox11101939
2076-3921